Medical marijuana patients showed improved brain function and executive performance after 3 months, opposite to recreational cannabis effects

After 3 months of medical marijuana treatment, patients showed improved executive function task performance, brain activation patterns that looked more like healthy controls, and notable decreases in opioid and benzodiazepine use.

Gruber, Staci A et al.·Frontiers in pharmacology·2017·Preliminary EvidenceObservational
RTHC-01392ObservationalPreliminary Evidence2017RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Observational
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Medical marijuana patients were assessed before starting treatment and after 3 months using fMRI while performing the Multi-Source Interference Test (MSIT). After treatment, patients showed improved task performance accompanied by changes in brain activation in the cingulate cortex and frontal regions.

Remarkably, brain activation patterns after treatment appeared more similar to those of healthy controls from previous studies than at pre-treatment, suggesting potential normalization of brain function. This contrasts sharply with recreational cannabis research, which typically shows worsened performance and altered brain activation.

Patients also reported improvements in clinical symptoms and health measures, and notable decreases in prescription medication use, particularly opioids and benzodiazepines.

Key Numbers

Improved MSIT performance after 3 months. Brain activation changes in cingulate cortex and frontal regions. Activation patterns moved toward healthy control norms. Notable decreases in opioid and benzodiazepine prescriptions.

How They Did This

Longitudinal observational study of medical marijuana patients assessed before initiating treatment and after 3 months. fMRI during the MSIT captured brain activation changes. Clinical state, health measures, and prescription medication use were also tracked.

Why This Research Matters

This is one of the first studies to directly measure brain function changes in medical marijuana patients over time. The finding that medical use may improve rather than impair executive function directly challenges the assumption that all cannabis use degrades cognition. The opioid and benzodiazepine reduction adds practical clinical significance.

The Bigger Picture

The contrast between medical and recreational cannabis effects on the brain is striking. Medical patients may be self-treating conditions (pain, anxiety) that were already impairing their cognition. Effective symptom relief through medical cannabis could remove that cognitive burden, explaining the improvement. This distinction between medical and recreational contexts may be one of the most important in cannabis research.

What This Study Doesn't Tell Us

Small pilot study without a control group. Improvement could reflect placebo effects, practice effects on repeated testing, or improvement in underlying conditions. The comparison to healthy controls is from previous studies, not matched. No randomization or blinding. Short follow-up period.

Questions This Raises

  • ?Would a larger controlled trial confirm these improvements?
  • ?Is the cognitive improvement driven by pain relief, sleep improvement, or reduced use of other medications?
  • ?Do the improvements persist with longer-term medical marijuana use?

Trust & Context

Key Stat:
Brain activation moved toward healthy norms after 3 months of medical marijuana
Evidence Grade:
Longitudinal observational study with fMRI. Innovative but uncontrolled and small, limiting causal conclusions.
Study Age:
Published in 2017. This is from an ongoing longitudinal study that has continued to publish findings on medical marijuana and cognition.
Original Title:
The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment.
Published In:
Frontiers in pharmacology, 8, 983 (2017)
Database ID:
RTHC-01392

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Watches what happens naturally without intervening.

What do these levels mean? →

Frequently Asked Questions

How can medical marijuana improve cognition when recreational marijuana impairs it?

The researchers suggest medical patients may have been cognitively impaired by their untreated conditions (pain, anxiety, insomnia). Effective symptom relief through medical marijuana may restore cognitive function to a more normal baseline. Additionally, medical users typically use different products, doses, and schedules than recreational users.

Did patients stop taking opioids?

The study reported "notable decreases" in opioid and benzodiazepine prescriptions after 3 months of medical marijuana treatment. This aligns with other research showing cannabis may serve as a substitute for these medications in some patients.

Read More on RethinkTHC

Cite This Study

RTHC-01392·https://rethinkthc.com/research/RTHC-01392

APA

Gruber, Staci A; Sagar, Kelly A; Dahlgren, Mary K; Gonenc, Atilla; Smith, Rosemary T; Lambros, Ashley M; Cabrera, Korine B; Lukas, Scott E. (2017). The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment.. Frontiers in pharmacology, 8, 983. https://doi.org/10.3389/fphar.2017.00983

MLA

Gruber, Staci A, et al. "The Grass Might Be Greener: Medical Marijuana Patients Exhibit Altered Brain Activity and Improved Executive Function after 3 Months of Treatment.." Frontiers in pharmacology, 2017. https://doi.org/10.3389/fphar.2017.00983

RethinkTHC

RethinkTHC Research Database. "The Grass Might Be Greener: Medical Marijuana Patients Exhib..." RTHC-01392. Retrieved from https://rethinkthc.com/research/gruber-2017-the-grass-might-be

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.